title: Postprandial exocrine pancreatic function during long-term treatment with the somatostatin analogue SMS 201-995 in acromegalic patients.
abstract: Long-term treatment with the somatostatin analogue SMS 201-995 (SMS) might impair exocrine pancreatic function, secretion of cholecystokinin (CCK) and pancreatic polypeptide (PP), and pancreatic size. In five acromegalics on chronic treatment with SMS, we investigated postprandial 6-h urinary excretion of p-aminobenzoic acid (PABA) and p-aminosalicylic acid (PAS) after s.c. injection of 100 micrograms SMS or placebo and after ingestion of 2 mmol nBT-PABA and 2 mmol PAS. In the acromegalics, urinary PABA/PAS ratio (reflecting exocrine pancreatic function) after SMS was similar to that after placebo (P greater than 0.10) and higher than in healthy volunteers (n = 8, P = 0.05). The initial inhibition of plasma CCK secretion by SMS was cancelled during the 3rd h after the meal, whereas PP release remained completely abolished. Pancreatic size as measured by ultrasonography, was not reduced in seven acromegalics compared with 14 healthy volunteers. It is concluded that despite a blunted release of the trophic hormone CCK, long-term treatment with SMS 201-995 neither induces an abnormally small pancreas nor deterioration of postprandial exocrine pancreatic function in patients with acromegaly.
authors.affiliation: Department of Internal Medicine, University Hospital Nijmegen, The Netherlands.
authors.forename: P A
authors.initials: PA
authors.lastname: Van Liessum
authors.forename: W P
authors.initials: WP
authors.lastname: Hopman
authors.forename: G F
authors.initials: GF
authors.lastname: Pieters
authors.forename: A G
authors.initials: AG
authors.lastname: Smals
authors.forename: A
authors.initials: A
authors.lastname: Tangerman
authors.forename: J B
authors.initials: JB
authors.lastname: Jansen
authors.forename: G
authors.initials: G
authors.lastname: Rosenbusch
authors.forename: C B
authors.initials: CB
authors.lastname: Lamers
mesh_terms: D010129:4-Aminobenzoic Acid / Q000652:urine; D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D010131:Aminosalicylic Acid / Q000652:urine; D002766:Cholecystokinin / Q000097:blood; D004435:Eating / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use; D010179:Pancreas / Q000187:drug effects*; D013997:Time Factors
chemical_list: D010131:Aminosalicylic Acid; D002766:Cholecystokinin; D015282:Octreotide; D010129:4-Aminobenzoic Acid